Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIM | P08670 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | MC1R | Q01726 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25978478 | 0.90 | VIM (0.57) | VIMCREBBPFURINBACE1MC4R | |
| SCHEMBL24162713 | 0.82 | VIM (0.59) | VIMFURINMC4RMC3RMC1R | |
| SCHEMBL29365901 | 0.79 | VIM (0.56) | VIMFURINBACE1 | |
| SCHEMBL21376479 | 0.71 | MC4R (0.55) | CREBBPMC4RMC3RMC1R | |
| SCHEMBL21376909 | 0.71 | MC4R (0.54) | CREBBPMC4RMC3RMC1R | |
| SCHEMBL21376568 | 0.71 | MC4R (0.54) | CREBBPMC4RMC3RMC1R | |
| SCHEMBL21376481 | 0.71 | MC4R (0.54) | CREBBPMC4RMC3RMC1R | |
| SCHEMBL21376771 | 0.71 | MC4R (0.54) | CREBBPMC4RMC3RMC1R | |
| SCHEMBL21376774 | 0.71 | MC4R (0.54) | CREBBPMC4RMC3RMC1R | |
| SCHEMBL21376308 | 0.71 | MC4R (0.54) | CREBBPMC4RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257420-A1 | COMPOUNDS FOR DRUG DELIVERY ACROSS BLOOD-BRAIN BARRIER | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257420-A1 | COMPOUNDS FOR DRUG DELIVERY ACROSS BLOOD-BRAIN BARRIER | TFRC, FABP7, LDLR | VIM 1789/4885CREBBP 1936/4885FURIN 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.